Research

#Clinical trials #Drug development #Drug discovery #Infectious diseases #Research

This week in drug discovery (9-13 August)

News round-up by DDW’s Megan Thomas for 9-13 August This week, DDW’s Megan Thomas has rounded up five stories which report positive data and findings from around the globe in the drug discovery sector. Preclinical data on oral polymer-based duodenal exclusion therapy Glyscend has presented data during the American… Read More

#News #Trending News

#Clinical trials #Research

Positive data for investigational P2X3 antagonist for refractory chronic cough

Evotec has been informed by Bayer about positive Phase IIb results from a clinical trial evaluating the efficacy and safety of the investigational P2X3 receptor antagonist eliapixant (BAY1817080) in patients with refractory chronic cough. The underlying molecule is a P2X3 receptor antagonist in Bayer’s clinical development pipeline originating from a… Read More

#News

#Clinical trials #Gene editing #Gene mutation #Gene therapy #Genetics / genomics #Research

Exploring gene-based medicine’s true potential

Listen to this article on the DDW Podcast: By Christopher Doyle, PhD, Director, IBC Services at WCG The Covid-19 pandemic spawned a flurry of research that culminated in the development of several vaccines that express viral proteins from recombinant or synthetic genetic material. The success of these new vaccines thrust the… Read More

#Business & Investment #Editor's Choice #Exclusive Content #News

#Clinical trials #Diabetes #Research #Type 2 diabetes

Preclinical data on oral polymer-based duodenal exclusion therapy

Glyscend has presented data during the American Diabetes Association 80th Scientific Sessions virtual meeting, from a study of its proprietary oral polymer duodenal exclusion therapy. The positive data were presented ahead of Glyscend’s Phase I clinical trials, which have commenced recruiting healthy subjects in South Australia. Glyscend is developing a… Read More

#News

#Clinical trials #Drug development #Drug discovery #Infectious diseases #mRNA #Novel therapeutics #Oncology #Research

This week in drug discovery (2-6 August)

News round-up by DDW’s Megan Thomas for 2-6 August This week has seen results released, research continued, and clinical trial phases completed. DDW’s Megan Thomas has rounded up her top five stories showing promise in the drug discovery industry. Cardiac patients receiving nasal gel showed reduction of S. aureus… Read More

#News #Trending News

#Bioinformatics #Biomedical research #Neurodegenerative disorders #Neuroscience #Research

Novel research identifies gene targets of stress hormones in the brain

New research has moved a step forward in understanding how glucocorticoid hormones (‘stress hormones’) act upon the brain and what their function is. The findings could lead to more effective strategies in the prevention and treatment of mental health disorders. The study, led by academics at the University of Bristol… Read More

#News #Trending News

#Drug development #Infectious diseases #Life sciences #Precision medicine #Research

Cerba Research awarded NIH contract for lab services

Cerba Research has been awarded a five-year contract for Clinical Central Laboratory Services from the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH). Findings from this research are said to be vital to NIAID’s efforts to advance vaccines, drugs, and diagnostic… Read More

#News

#Diabetes #Nanomedicine / nanotechnology #Research

New drug provides potential improved treatment for blindness

A potential improved treatment for two of the leading causes of blindness – age and diabetes-related eye problems – has been demonstrated in research involving University of Queensland expert Professor Di Yu of the UQ Diamantina Institute, who collaborated with scientists from the Chinese Academy of Sciences and Beijing Chaoyang… Read More

#News

#Precision medicine #Report #Research

The Operationalisation of Precision Medicine report

Public Policy Projects (PPP) has launched a new report called ‘The Operationalisation of Precision Medicine.' The report, which is now available to download, has been created in partnership with AstraZeneca. Precision medicine is a development in medical history that has the potential to ensure better outcomes for patients. The UK… Read More

#Market Reports #News #Trends & Analysis

#Cell and gene therapy #Cell and Gene Therapy Catapult #Gene therapy #Neurodegenerative disorders #Research

Gene therapy enables new treatments for neurodegenerative diseases

The University of Sheffield and the Cell and Gene Therapy Catapult have launched a gene therapy programme which could pave the way for novel treatments for neurodegenerative diseases. The research has been awarded £513,141 from LifeArc and the Motor Neurone Disease Association to test the feasibility and efficiency of a… Read More

#News

#Alzheimer's #Drug development #Pharma #Research

New data supports targeting Trk receptors for treating Alzheimer’s

AlzeCure Pharma’s presentation and poster regarding the clinical candidate drug ACD856 for Alzheimer’s disease, presented at the Alzheimer’s Association International Conference (AAIC) 2021 on July 26-30 in Denver, USA, are now available on its website. The abstract, ACD856 – a novel positive allosteric modulator of Trk-signaling in clinical development for… Read More

#News

#Animal testing #R&D #Research

FRAME comment on the new UK animal R&D statistics

The UK government has released a national statistics report, “Annual Statistics of Scientific Procedures on Living Animals, Great Britain, 2020”. DDW recently reported the ABPI comment. The medical research charity FRAME’s Education & Outreach Manager Amy Beale has made further comment. Beale said: “Whilst the headline figures in the… Read More

#News

#Cancer research #Checkpoint inhibitor therapies #Research #Therapeutics

Agreement signed to profile patients in immuno-oncology trial

Oncimmune Holdings has signed an autoantibody profiling contract with Dana-Farber Cancer Institute in Boston, Massachusetts. Dana-Farber, a clinical affiliate and research institute of Harvard Medical School, is a cancer research organisation and its cancer hospitals have more than 1,100 therapeutic and non-therapeutic clinical trials in progress. Under this agreement, Oncimmune… Read More

#News

#Blood donation #Drug development #Research

BioIVT opens UK blood donor centre at London’s White City Campus  

BioIVT has moved its London blood donor centre to Imperial College London’s White City Campus, which is four times larger than its previous facility. BioIVT has seven global blood donor centres and supports the work of about 30,000 researchers worldwide. “We are responding to a rapidly… Read More

#News

#Drug development #Drug innovation #Funding #Research #Therapeutics

Orbit Discovery plans growth in peptide discovery business

Orbit Discovery has raised US$7.6 million which will be used to accelerate its growth as a provider of peptide discovery services to the biotechnology and pharmaceutical industry. Orbit Discovery’s novel bead-based and microfluidic technology platform enables the screening of peptide libraries for target binding and subsequent activity in cell-based functional… Read More

#News